Clinical factors associated with baseline blood eosinophils among patients with asthma or COPD: NOVELTY study

H. Müllerová* (Corresponding Author), D. K. Finch, A. Agustí, M. Alacqua, G. P. Anderson, R. Beasley, L. Belton, A. De Giorgio-Miller, J. M. Fitzgerald, R. Hughes, I. D. Pavord, D. Price, E. Rapsomaniki, M. Sadatsafavi, J. Vestbo, E. H. Bel

*Corresponding author for this work

Research output: Contribution to conferenceAbstract

Abstract

Background: Blood eosinophil count (bEOS) is an important biomarker in obstructive lung disease. NOVELTY (NCT02760329) is a global, prospective, observational study with potential to identify obstructive lung disease phenotypes associated with differential outcomes, using biomarkers and clinical features. Objective: To evaluate factors associated with bEOS in patients with either physician-assigned asthma or COPD in NOVELTY.
Original languageEnglish
Publication statusAccepted/In press - 27 Jul 2020
Event30th ERS International Congress - Virtual Event
Duration: 7 Sep 20209 Sep 2020

Conference

Conference30th ERS International Congress
Period7/09/209/09/20

Fingerprint Dive into the research topics of 'Clinical factors associated with baseline blood eosinophils among patients with asthma or COPD: NOVELTY study'. Together they form a unique fingerprint.

Cite this